Shanghai Kaibao (300039.SZ): KBZ24020 approved to conduct clinical trials for acute ischemic stroke.

Smart Financial APP News, Shanghai Kaibao (300039.SZ) announced that the company has recently received the "Notice of Approval for Drug Clinical Trial" issued by the National Medical Products Administration. After review, the clinical trial application KBZ24020 submitted on August 25, 2025 meets the relevant requirements for drug registration. With further improvement of the clinical trial plan, the company has been authorized to conduct clinical trials for acute ischemic stroke.